Arcellx, Inc. (ACLX)
115.07
0.00 (0.00%)
USD |
NASDAQ |
May 04, 16:00
Arcellx Cash from Investing (Quarterly) : 57.80M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Gilead Sciences, Inc. | -1.835B |
| Eli Lilly & Co. | -3.916B |
| Merck & Co., Inc. | -- |
| Bristol Myers Squibb Co. | -131.00M |
| BioMarin Pharmaceutical, Inc. | 725.53M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -58.18M |
| Cash from Financing (Quarterly) | 1.634M |
| Free Cash Flow | -212.58M |
| Free Cash Flow Per Share (Quarterly) | -1.018 |
| Free Cash Flow to Equity (Quarterly) | -59.06M |
| Free Cash Flow to Firm (Quarterly) | -58.94M |
| Free Cash Flow Yield | -3.27% |